ArticleBioengineering (Basel, Switzerland)2026
Artificial Intelligence Algorithm Based on Genetics to Predict Responses to Interferon-Beta Treatment in Multiple Sclerosis Patients.
Article in Bioengineering (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Multiple sclerosis (MS) is an inflammatory disease of the central nervous system (CNS) that impacts nearly 3 million people worldwide. While the etiology and pathogenesis of MS are not yet fully understood, current evidence suggests that it results from complex interactions between genetic and environmental conditions. Clarifying the autoimmune mechanisms underlying MS remains a central objective in the development of effective therapeutic strategies. Interferon-beta (IFN-β) is one of the most frequently prescribed disease-modifying treatments for individuals with MS. However, despite its established efficacy, recent studies report that approximately 30-50% of patients exhibit inadequate response to IFN-β, largely due to genetic variability. Machine learning (ML), a branch of artificial intelligence (AI), employs data-driven computational models to enhance predictive accuracy and classification. In recent MS research, unsupervised learning techniques such as hierarchical clustering and K-means have been applied for classification purposes. However, these methods often fail to yield optimal solutions because they require numerous arbitrary decisions and perform adequately only when datasets contain clusters of similar sizes and lack significant outliers. Fuzzy systems (FSs) are designed to model complex, ambiguous real-world phenomena. In this study, an AI algorithm incorporating a fuzzy system, informed by expert neurologist input, is proposed to enhance the assignment of unknown class labels related to IFN-β response in MS patients. Additionally, a genetic algorithm (GA) is introduced to identify optimal solutions within the search space, facilitating hyperparameter optimization of a deep learning (DL) model trained with genetic biomarkers to identify patients likely to benefit from this therapy. Experimental results demonstrate that the fuzzy system achieved 80% classification efficiency, in contrast to 64% with conventional hierarchical clustering. Furthermore, an artificial neural network (ANN) model, with hyperparameters optimized by the GA, achieved an accuracy of 0.8-1.0, surpassing the multi-layer perceptron (MLP), which achieved 0.6-0.8 accuracy using conventional tuning methods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.